Skip to main content
CODX logo

CODX · Co-Diagnostics, Inc.

Track CODX — free
$0.26 -0.01 (-4.12%) At close · Nov 13
Market Cap
$2.72M
Shares
10.51M
Volume · Nov 13 591.94K Avg daily vol (3M) 1.97M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.26 Open$0.27 Day$0.25–0.27 52W close$0.26–11.61 Avg vol 30d3.9M Short int981K · 9.3% of shares · 2.2d Short vol34% Last earningsNov 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Feb 8, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 13
Current report 8-K
Shareholders expand incentive plan and authorize reverse stock splits

Co-Diagnostics shareholders increased the equity incentive plan reserve by 2,000,000 shares to 2,223,333, approved warrants for 3,404,724 shares at $1.56, and authorized reverse stock splits of not less than 1-for-2 and up to 1-for-750.

Director or officer change, or executive pay, Shareholder vote results
3 source passages
The Plan Amendment increases the number of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), authorized for issuance under the Plan by 2,000,000 shares. As amended, the Plan provides that, subject to adjustment as provided in the Plan, the maximum number of shares of Common Stock that may be issued or transferred under awards granted under the Plan is 2,223,333 shares. Proposal No. 6: A proposal to approve the potential exercise of the new warrants to purchase an aggregate of 3,404,724 shares of common stock at an exercise price of $1.56 per share that were issued on August 3, 2026 pursuant to that certain inducement agreement dated July 30, 2026, for which stockholder approval is required in accordance with Nasdaq Listing Rule 5635(d). This proposal was approved. Proposal No. 8: A proposal to approve an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by our Board at any time within twelve months following the Special Meeting, without further approval or authorization of our stockholders, as described in the Proxy Statement. This proposal was approved. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash shortfall raises going-concern uncertainty

Co-Diagnostics reported $0.7 million cash and cash equivalents at September 30, 2026, versus total current liabilities of $2.5 million, and said additional capital is required, creating substantial doubt about its ability to continue as a going concern.

Revenue $282.88K ▲ 94.6% Net loss $6.31M Diluted EPS -$1.01
Read from the MD&A section
4 source passages
Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. At September 30, 2026, we had cash and cash equivalents of $0.7 million. Additionally, our total current assets at September 30, 2026, were $1.9 million compared to total current liabilities of $2.5 million. Although this financing provided additional near-term liquidity, the Company will require additional capital to fund its ongoing operations, and there can be no assurance that additional financing will be available on acceptable terms, or at all. These uncertainties create substantial doubt about our ability to continue as a going concern. Open the document at this passage
Nov 10
Current report 8-K
Revenue $0.3 million; net loss $6.3 million

Co-Diagnostics reported third-quarter revenue of $0.3 million versus $0.1 million in the third quarter of 2025, but net loss was $6.3 million versus $5.9 million. Cash and cash equivalents totaled $0.7 million as of September 30, 2026.

Financial results, Regulation FD disclosure
4 source passages
Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2026. Revenue of $0.3 million, compared to $0.1 million in the third quarter of 2025 Net loss of $6.3 million, or $1.01 per basic and diluted share, compared to a net loss of $5.9 million, or $4.66 per basic and diluted share, in the third quarter of 2025. Cash and cash equivalents totaled $0.7 million as of September 30, 2026 Open the document at this passage
Nov 4
Registration statement S-3
Co-Diagnostics Registers Astor Resale of 39,594,495 Shares

Co-Diagnostics registered up to 39,594,495 common shares for J.J. Astor & Co.’s resale, including conversion shares and 600,000 commitment shares tied to convertible notes. Astor funded $2.1 million initially, with another $1.0 million available; Co-Diagnostics receives no resale proceeds.

Read from the first part of this long document
5 source passages
This prospectus relates to the offer and resale by J.J. Astor & Co., a Utah corporation (“Astor”) identified in this prospectus or its donees, pledgees, assignees, transferees, distributees or other successors-in-interest (collectively, with Astor, the “Selling Stockholder”) of up to an aggregate of 39,594,495 shares (the “Shares”) of our common stock, par value $0.001 per share (the “common stock”). At the initial closing, the Selling Stockholder funded $2.1 million and the Company issued a senior secured convertible installment promissory note having an original principal amount of $2.835 million (the “Initial Note”). Subject to the terms and conditions of the Loan Agreement, the Company may borrow an additional $1.0 million and issue an additional senior secured convertible installment promissory note having an original principal amount of $1.35 million (the “Additional Note” and, together with the Initial Note, the “Notes”). In connection with the transaction, the Company also issued 600,000 shares of common stock to the Astor as commitment shares (the “Commitment Shares”). We will not receive any proceeds from the resale of the Shares by the Selling Stockholder. Open the document at this passage
Oct 26
Proxy statement DEF 14A
Proxy statement

Co-Diagnostics, Inc. will ask shareholders on November 13, 2026 to authorize reverse stock splits of not less than 1-for-2 and up to 1-for-750, approve potential exercise of warrants for 3,404,724 shares at $1.56 per share, and address director elections and equity compensation.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$858,888
Trailing 12 months
Net income (TTM)
−$47.48M
Trailing 12 months
Revenue growth YoY
+94.6%
Year over year
Operating margin
-5,614.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1,000.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$714,803
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+396.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
9.3%
Latest settlement · 2.2 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26

TL;DR. Co-Diagnostics reported a $6.3M net loss on $166K of Q2 revenue while submitting its FDA 510(k) and CLIA waiver application for the Co-Dx PCR Flu A/B & RSV test, advancing TB clinical work in India, and completing a proof-of-concept Ebola assay. Cash fell to $3.6M from $11.9M at year-end 2025, prompting the company to flag potential dilutive financings to support commercialization.

Bullish
  • + Submitted 510(k) and CLIA waiver application for the Flu A/B & RSV test after completing clinical studies with 1,400+ patients and 27 analytical studies. new
  • + Reduced net loss to $6.3M from $7.7M and cut operating expenses to $6.3M from $8.2M year-over-year. new
  • + Completed proof-of-concept Ebola assay on the Co-Dx PCR Pro and supplied Bundibugyo test kits for evaluation in India. new
Bearish
  • − Revenue remains minimal at $166K, with gross profit declining to $121K from $131K year-over-year. new
  • − Cash and cash equivalents declined to $3.6M from $11.9M at year-end 2025, and management flagged potential dilutive financings ahead. new
  • − Management expects continued operating losses in the near term with commercialization still pending. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −88%
below
Price vs 50-day avg −68%
below
RSI (14) 23
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −60%
trailing
6-month return −97%
trailing
YTD return −95%
this year
Relative strength −98%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
23 of 25 funds reported for Sep 30 · net -12.0K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.34% of shares out · ▲ +49.5% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 3-yr range
Squeeze score 69
elevated · 0–100
Fundamentals
Strong
Revenue growth −84%
Y/Y
Gross margin 64%
contracting
EPS growth +5%
Y/Y
Free cash flow $-29.8M
Buyback $30.0M
authorized
Balance sheet $11.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 221%
annualized · 1-yr
Max drawdown −98%
past year
ATR 27.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Guided vs delivered · last 8 settled
First quarter revenue First Quarter Fiscal 2022
guided $21M – $22M
$22.7M Beat +5.6%
Diluted EPS First Quarter Fiscal 2022
guided $0.17 – $0.20
$0.34 Beat +83.8%
Revenue full year of 2021
guided $96M – $100M
$97.89M In line
Diluted earnings per share full year of 2021
guided $1.07 – $1.16
$1.23 Beat +10.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−88% Bearish
Price vs 50-day avg
−68% Bearish
RSI (14)
23 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
23 of 25 funds reported for Sep 30 · net -12.0K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.34% of shares out · ▲ +49.5% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $12
vs 200-day avg -88% vs 50-day avg -68%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP 5.8M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CODX
Co-Diagnostics, Inc.
this stock
$2.72M — -84.1% — 9.3%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
25
% held
5.6%
Reported
23 of 25
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
981.3K
Days to cover
2.2d
Change
+325.0K sh
View
Short Volume
Short vol %
34%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
888
Value
$1.1K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
71.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$622.5K
Net income (FY)
$-46.9M
EPS diluted
$-35.25
View
Buybacks
Authorized
$30.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
34

Co-Diagnostics shareholders increased the equity incentive plan reserve by 2,000,000 shares to 2,223,333, approved warrants for 3,404,724 shares at $1.56, and authorized reverse stock splits of not less than 1-for-2 and up to 1-for-750.

View
Exempt Offerings
Offering
$47.2M
Filed
Jan 14, 2022
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Co-Diagnostics Reports Third Quar…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
CODX +0.7% -60.5% -97.2% -29.5% -94.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -1.9% -59.3% -97.7% -29.3% -105.5%

Capital returns

Buyback program · as of Mar 1, 2022
Authorized
$30.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1692415 CUSIP 189763204 13F (30d) 30 filings 20 filers Visit website Investor relations